ALGOTHERAPEUTIX
15.12.2020 08:17:14 CET | Business Wire | Press release
France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today it has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01. The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021.
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. Given a positive outcome of the approved Phase 1 study, the company intends to initiate Phase 2 by the end of 2021.
Stéphane Thiroloix , Founder & CEO of AlgoTherapeutix, says: “I am thrilled by the entry of ATX01 in clinical development as it represents a great step forward towards providing CIPN patients with a response to the crippling pain they endure.”
Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.
Over the last two years, AlgoTherapeutix took ATX01 from exploratory prototype to final formulation, established its pharmacological profile, conducted a full pre-clinical toxicology package, and scaled-up manufacturing to enable clinical supply production. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
A recent publication in the “Journal of Pain” describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002 )
About AlgoTherapeutix
AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé. Their lead programme ATX01 is in clinical development in Chemotherapy-Induced Peripheral Neuropathy. More information at www.algotx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frost & Sullivan 2026 Technology Innovation Leadership Best Practices Recognition for Ohmium International18.6.2026 10:31:00 CEST | Press release
Ohmium International Inc., a leading manufacturer of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has received the 2026 Global Technology Innovation Leadership Recognition for Best Practices in the PEM electrolyzer and green hydrogen industry by Frost & Sullivan. This recognition highlights Ohmium's continued advancement of cutting-edge PEM technology into scalable, real-world hydrogen solutions that address critical energy and industrial challenges across global markets. Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition for Best Practices to organizations that demonstrate exceptional achievement in leveraging technology to drive market transformation and measurable business impact. The firm evaluates companies across two core dimensions: technology leverage and business impact. Ohmium excelled across both measures, demonstrating commitment to innovation, stage gate efficiency, commercialization, and applic
Infobip Ranked in Top 25 of Fortune's Europe's Most Innovative Companies 202618.6.2026 10:11:00 CEST | Press release
A strong result highlighting Infobip’s momentum in European tech innovation Global AI-first cloud communications platform Infobip has been ranked in the top 25 of Fortune's Europe's Most Innovative Companies 2026, marking a strong rise on this year's list. The announcement was made at VivaTech in Paris. Last year, Infobip entered Fortune's inaugural ranking at number 68. This year, it climbs to 16! The Fortune Europe's Most Innovative Companies list, in partnership with the global research firm Statista, evaluates companies based on innovation culture, product development, and process improvements. Infobip's rise reflects the accelerating momentum behind its AI-first strategy, including the launch of Infobip AgentOS, its AI-native fully managed solution that orchestrates autonomous AI-driven customer journeys at scale. Infobip's innovation credentials are further reinforced by its role in Important Project of Common European Interest (IPCEI) for Next Generation Cloud Infrastructure and
Philip Morris International Announces New Regional Leadership18.6.2026 10:00:00 CEST | Press release
The appointments strengthen the company’s leadership pipeline as it moves towards a smoke‑free future Philip Morris International (PMI) (NYSE: PM) announced a series of regional leadership appointments that support its ongoing shift toward a smoke‑free future. Effective August 1, 2026, Marco Hannappel has been appointed President, Europe Region, and Can Kuterdem has been appointed President, Latin America & Canada Region. These appointments build on PMI’s evolved organizational model announced in late 2025, under which Gijs de Best serves as President, South Asia, Indochina, CIS & Middle East & Africa Region, and Vassilis Gkatzelis continues as President East & Southeast Asia, Pacific and PMI Global Travel Retail Region. The four regional presidents report to Frederic de Wilde - CEO of the International Business Unit of PMI and are the key operational leaders for the unit that generates the large majority of total PMI net revenues. Marco Hannappel takes over the role of President, Euro
Blooming Future Launches Operations as Part of Braskem’s Expanding Sustainable Fleet18.6.2026 10:00:00 CEST | Press release
Designed for long-range transport of essential raw materials, Blooming Future strengthens Braskem’s commitment to safer, more efficient, and lower-emission shipping. Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK), the largest polyolefins producer in the Americas and global leader in the production of biopolymers on an industrial scale announces today that Braskem Trading & Shipping (BT&S) has launched the maiden voyage of Blooming Future, a next-generation LR1 chemical and product oil tanker designed to transport essential raw materials with greater efficiency and a lower carbon footprint. The vessel was formally named at a ceremony in China on May 8. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618295583/en/ Braskem's Blooming Future “Blooming Future will carry naphtha to support our industrial production, while operating at optimized speed to reduce fuel consumption and emissions. The vessel is as wid
New Industry Study Finds Quantum Computing Has Entered a Capability Era, With Early Movers Building an Advantage Later Entrants Will Struggle to Close18.6.2026 09:00:00 CEST | Press release
State of Quantum 2026, based on tracked transaction data, a survey of 107 practitioners, and 19 interviews, finds 89% of enterprises surveyed are now hands-on with quantum but only 3% have reached scaled deployment, as the market shifts from accessing quantum systems to building capability around them. Quantum computing has moved past the question of whether organizations can access a quantum system and onto whether they can build something useful around one. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618639340/en/ State of Quantum 2026 is based on independently conducted research and analysis, authored by The Quantum Insider (Resonance), published by IQM Quantum Computers, and supported by OpenOcean. According to the State of Quantum 2026, the fourth annual industry study published today by IQM Quantum Computers, which is nearing its planned listing on the Nasdaq Global Select Market through its merger with Real Asse
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom